Protagenic Ev To Sales from 2010 to 2024

PTIX Stock  USD 1.50  0.01  0.67%   
Protagenic Therapeutics EV To Sales yearly trend continues to be fairly stable with very little volatility. EV To Sales will likely drop to 0.11 in 2024. EV To Sales is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. View All Fundamentals
 
EV To Sales  
First Reported
2010-12-31
Previous Quarter
0.12
Current Value
0.11
Quarterly Volatility
582.0514422
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 87.3 K or Selling General Administrative of 1.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Protagenic Therapeutics Technical models . Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Ev To Sales Growth Pattern

Below is the plot of the Ev To Sales of Protagenic Therapeutics over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Protagenic Therapeutics' EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ev To Sales10 Years Trend
Slightly volatile
   Ev To Sales   
       Timeline  

Protagenic Ev To Sales Regression Statistics

Arithmetic Mean281.26
Geometric Mean0.69
Coefficient Of Variation206.94
Mean Deviation449.85
Median0.10
Standard Deviation582.05
Sample Variance338,784
Range1.4K
R-Value(0.69)
Mean Square Error188,939
R-Squared0.48
Significance0
Slope(90.37)
Total Sum of Squares4.7M

Protagenic Ev To Sales History

2024 0.11
2023 0.12
2013 0.1

About Protagenic Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Protagenic Therapeutics income statement, its balance sheet, and the statement of cash flows. Protagenic Therapeutics investors use historical funamental indicators, such as Protagenic Therapeutics's Ev To Sales, to determine how well the company is positioned to perform in the future. Although Protagenic Therapeutics investors may use each financial statement separately, they are all related. The changes in Protagenic Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Protagenic Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Protagenic Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Sales 0.12  0.11 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Protagenic Therapeutics is a strong investment it is important to analyze Protagenic Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Protagenic Therapeutics' future performance. For an informed investment choice regarding Protagenic Stock, refer to the following important reports:
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Protagenic Stock analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Commodity Directory
Find actively traded commodities issued by global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Global Correlations
Find global opportunities by holding instruments from different markets
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Protagenic Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.15)
Return On Assets
(0.46)
Return On Equity
(0.94)
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.